Kevin Young Joins Gilead Sciences as Executive Vice President, Commercial Operations

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 14, 2004--Gilead Sciences (Nasdaq:GILD) announced today that Kevin Young has joined the company as Executive Vice President, Commercial Operations, a newly-created position following the company's expansion and reorganization of its commercial operations earlier this year. Mr. Young will report to President and Chief Executive Officer John C. Martin, PhD, and will have responsibility for global commercial operations and strategy for Gilead's product portfolio.

"Kevin's experience and understanding of the complex global marketplace in which Gilead operates will be invaluable as our company continues to grow," said Dr. Martin. "With the recent U.S. launch of Truvada(TM) (emtricitabine and tenofovir disoproxil fumarate) and the future introduction of the product in Europe and other geographies, Kevin's leadership will help Gilead to maximize and build on our commercial successes."

Mr. Young has spent 20 years in the biopharmaceutical industry, first with Zeneca Pharmaceuticals (formerly ICI Pharmaceuticals) and more recently, Amgen Inc. During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States. His most recent position was Head of the U.S. Inflammation Business Unit, leading the re-launch of Enbrel following the acquisition of Immunex. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England and has completed the Executive Program at the University of Michigan, School of Business Administration.

"The opportunity to join the Gilead team - a team that has launched four new products in the past three years - is a tremendous one," said Mr. Young. "Gilead has built a strong and sustainable antiviral franchise, and is positioned for continued growth well into the future. I look forward to working with my new colleagues to further the company's mission of delivering therapeutic advancements to patients worldwide."

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that regulatory authorities may not grant approval of Truvada or that future approvals may be delayed. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. Risks are described in detail in the Gilead Annual Report on Form 10-K for the year ended December 31, 2003 and in Gilead's Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

Truvada is a trademark of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) SOURCE: Gilead Sciences, Inc.